Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:58:41 EDT Sat 05 Jul 2025
Enter Symbol
or Name
USA
CA



News for U:JNJ from 2024-07-05 to 2025-07-04 - 123 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-06-23 07:32U:JNJNews ReleaseIMAAVY(TM) (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
2025-06-15 03:15U:JNJNews ReleaseInvestigational combination of first-in-class bispecifics TALVEY(TM) and TECVAYLI(TM) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
2025-06-13 11:00U:JNJNews ReleaseJohnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
2025-06-12 11:00U:JNJNews ReleaseNew results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
2025-06-11 08:05U:JNJNews ReleaseNew data show TREMFYA(TM) (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
2025-06-10 16:51U:JNJNews ReleaseJohnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
2025-06-03 10:45U:JNJNews ReleaseEarly results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
2025-06-03 10:45U:JNJNews ReleaseSingle infusion of CARVYKTI(TM) (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
2025-06-03 10:45U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
2025-06-03 08:00U:JNJNews ReleaseJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
2025-05-28 16:43U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2025-05-21 16:40U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
2025-05-20 18:21U:JNJNews ReleaseU.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
2025-05-14 16:40U:JNJNews ReleaseJohnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-09 08:05U:JNJNews ReleaseIcotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
2025-05-08 08:12U:JNJNews ReleaseJohnson & Johnson expands efforts to champion the nursing workforce globally
2025-05-05 08:05U:JNJNews ReleaseTREMFYA(TM) (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
2025-05-05 08:05U:JNJNews ReleaseTREMFYA(TM) (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
2025-04-30 08:29U:JNJNews ReleaseJohnson & Johnson receives FDA approval for IMAAVY(TM) (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
2025-04-28 16:22U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
2025-04-26 14:00U:JNJNews ReleaseJohnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
2025-04-26 13:50U:JNJNews ReleaseJohnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
2025-04-24 13:17U:JNJSEDAR Interim MD & ASEDAR Interim MD & A
2025-04-24 13:11U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-04-21 09:36U:JNJNews ReleaseJohnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
2025-04-16 16:28U:JNJNews ReleaseJohnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
2025-04-15 08:55U:JNJNews ReleaseNYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
2025-04-15 08:55U:JNJNews ReleaseNYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates
2025-04-15 06:25U:JNJNews ReleaseJohnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
2025-04-15 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q1 2025 Results
2025-04-10 08:05U:JNJNews ReleaseIcotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
2025-04-08 03:00U:JNJNews ReleaseJohnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)
2025-04-07 16:25U:JNJNews ReleaseJohnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
2025-04-04 08:05U:JNJNews ReleaseTREMFYA(TM) (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
2025-04-02 08:44U:JNJNews ReleaseJohnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
2025-04-01 16:06U:JNJNews ReleaseJohnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
2025-03-31 22:20U:JNJNews ReleaseJohnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
2025-03-26 11:45U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
2025-03-26 08:03U:JNJNews ReleaseNew nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
2025-03-21 06:00U:JNJNews ReleaseJohnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
2025-03-20 18:12U:JNJNews ReleaseU.S. FDA approves TREMFYA(TM) (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
2025-03-20 08:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
2025-03-18 08:03U:JNJNews ReleaseNipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjogren's disease, has now received Fast Track designation
2025-03-10 08:00U:JNJNews ReleaseIcotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
2025-03-08 09:00U:JNJNews ReleaseIcotrokinra results show potential to set a new standard of treatment in plaque psoriasis
2025-03-07 14:33U:JNJSEDAR MD & ASEDAR Annual Report
2025-03-07 14:27U:JNJSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-03-05 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on First-Quarter Results
2025-03-04 16:15U:JNJNews ReleaseJohnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
2025-02-21 07:00U:JNJNews ReleaseTREMFYA(TM) (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
2025-02-13 08:05U:JNJNews ReleaseNew nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
2025-02-03 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
2025-01-23 05:35U:JNJNews ReleaseFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
2025-01-22 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q4 and Full-Year 2024 Results
2025-01-21 08:00U:JNJNews ReleaseSPRAVATO(TM) (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
2025-01-15 08:00U:JNJNews ReleaseNew Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
2025-01-13 06:32U:JNJNews ReleaseJohnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
2025-01-13 06:30U:JNJNews ReleaseJohnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
2025-01-09 08:04U:JNJNews ReleaseNipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
2025-01-08 08:00U:JNJNews ReleaseJohnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
2025-01-07 08:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
2025-01-02 08:00U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for First Quarter 2025
2024-12-12 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-10 08:00U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2024-12-09 19:30U:JNJNews ReleaseCARVYKTI(TM) (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
2024-12-09 08:00U:JNJNews ReleaseWarm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
2024-12-08 19:30U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
2024-12-08 12:33U:JNJNews ReleaseTECVAYLI(TM) (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
2024-12-08 11:21U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
2024-12-02 08:00U:JNJNews ReleaseJohnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA(TM) (guselkumab)
2024-11-22 08:00U:JNJNews ReleaseJohnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA(TM) (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
2024-11-19 09:02U:JNJNews ReleaseJohnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
2024-11-18 16:30U:JNJNews ReleaseIcotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
2024-11-14 10:00U:JNJNews ReleaseNipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjogren's disease study
2024-11-11 16:05U:JNJNews ReleaseNipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjogren's disease
2024-11-08 07:00U:JNJNews ReleaseJohnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO(TM) / DARZALEX(TM) as subcutaneous monotherapy for high-risk smoldering multiple myeloma
2024-11-07 08:00U:JNJNews ReleaseJohnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
2024-11-04 15:11U:JNJNews ReleaseEmpower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
2024-10-28 15:40U:JNJSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-10-28 07:30U:JNJNews ReleaseTREMFYA(TM) (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
2024-10-25 08:05U:JNJNews ReleaseNew SPECTREM study findings reveal TREMFYA(TM) (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
2024-10-24 08:00U:JNJNews ReleaseJohnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
2024-10-15 08:00U:JNJNews ReleaseNipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
2024-10-15 06:25U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
2024-10-15 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q3 2024 Results
2024-10-10 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
2024-10-10 08:00U:JNJNews ReleaseTREMFYA(TM) (guselkumab) demonstrates impressive results across biologic-naive and biologic-refractory patients in Crohn's disease and ulcerative colitis
2024-10-09 08:00U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of V-Wave
2024-10-04 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
2024-10-02 09:00U:JNJNews ReleaseERLEADA(TM) (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
2024-09-30 16:05U:JNJNews ReleaseJohnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO(TM)-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-30 08:05U:JNJNews ReleaseJohnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
2024-09-27 16:30U:JNJNews ReleaseCARVYKTI(TM) is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
2024-09-27 13:05U:JNJNews ReleaseDARZALEX(TM) (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
2024-09-27 13:00U:JNJNews ReleaseDARZALEX FASPRO(TM)-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
2024-09-27 08:05U:JNJNews ReleaseNovel combination of TALVEY(TM) (talquetamab-tgvs) and TECVAYLI(TM) (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary
2024-09-27 08:00U:JNJNews ReleaseTALVEY(TM) (talquetamab-tgvs) and DARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
2024-09-20 15:43U:JNJNews ReleaseJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
2024-09-19 18:54U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
2024-09-16 02:50U:JNJNews ReleaseNeoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
2024-09-15 02:30U:JNJNews ReleaseNew data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
2024-09-14 09:45U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
2024-09-14 03:10U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
2024-09-11 18:22U:JNJNews ReleaseTREMFYA(TM) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
2024-09-10 17:15U:JNJNews ReleaseDexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(TM) (amivantamab-vmjw)
2024-09-08 13:47U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
2024-09-05 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2024-08-29 08:00U:JNJNews ReleaseJohnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
2024-08-27 08:00U:JNJNews ReleaseJohnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
2024-08-26 08:00U:JNJNews ReleaseJohnson & Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
2024-08-20 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire V-Wave
2024-08-20 07:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
2024-08-07 17:00U:JNJNews ReleaseGroundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
2024-08-06 09:00U:JNJNews ReleaseAlzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
2024-07-30 18:45U:JNJSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-07-30 18:42U:JNJNews ReleaseDARZALEX FASPRO(TM) (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
2024-07-29 16:00U:JNJNews ReleaseJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
2024-07-23 16:00U:JNJNews ReleaseJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-22 08:00U:JNJNews ReleaseJohnson & Johnson seeks U.S. FDA approval of SPRAVATO(TM) (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
2024-07-17 06:25U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
2024-07-17 06:20U:JNJNews ReleaseJohnson & Johnson reports Q2 2024 results
2024-07-15 08:05U:JNJNews ReleaseNKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
2024-07-11 07:30U:JNJNews ReleaseJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26